01:37 PM EST, 01/02/2025 (MT Newswires) -- Neumora Therapeutics ( NMRA ) said Thursday its phase 3 study of navacaprant in major depressive disorder failed to meet its primary endpoint.

RBC downgraded Neumora to sector perform from outperform, with a price target of $4.

Shares of Neumora slumped more than 81% following a jump in intraday trading volume to over 32.3 million from a daily average of about 1.1 million.

Aptorum ( APM ) said Thursday it struck a deal to sell about 1.5 million class A shares to several institutional investors at $2 per share.

Shares sank 24%, with intraday trading volume surging to over 12.4 million versus a daily average of about 2.0 million.

H.B. Fuller ( FUL ) said Thursday it expects fiscal 2024 adjusted earnings per share of $3.84, down from a prior outlook of $4.10 to $4.20. Analysts polled by FactSet are expecting full-year EPS of $4.15.

Shares retreated 7% as intraday trading volume climbed to more than 413,000 from a daily average of roughly 280,000.

Price: 1.93, Change: -8.67, Percent Change: -81.80